OverviewChartNewsTraderScreen

HSBC Call 100 BAYN 17.12.2025/  DE000TT8FS83  /

Frankfurt Zert./HSBC
11/06/2024  21:35:19 Chg.0.000 Bid11/06/2024 Ask11/06/2024 Underlying Strike price Expiration date Option type
0.001EUR 0.00% 0.001
Bid Size: 120,000		 0.023
Ask Size: 20,000		 BAYER AG NA O.N. 100.00 EUR 17/12/2025 Call
GlobeNewswire 11/06 Banks are making climate commitments, but are they actually making a difference?
GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 30/05 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 30/05 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 14/05 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 02/05 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 18/04 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 16/04 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 11/04 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 09/04 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 25/03 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 14/03 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 06/03 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 05/03 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 04/03 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 04/03 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 15/02 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 13/02 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 13/02 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
TeleTrader 29/01 Bayer down over 5% after latest $2.25B Roundup ruling
TeleTrader 17/01 Bayer to cut jobs amid 'difficult situation'
GlobeNewswire 05/01 AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GlobeNewswire 04/01 AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...